{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:30:40Z","timestamp":1792668640509,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:28:45Z","timestamp":1720949325000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions"],"prefix":"10.1016","volume":"25","author":[{"given":"Christopher E.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.07.005_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0002","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.07.005_bib0004","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0006","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2023-185076","article-title":"Incidence of richter transformation in patients with chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL): a cohort study evaluating different therapeutic eras","volume":"142","author":"Hampel","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0007","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood-2018-99-112442","article-title":"Risk factors associated with richter's transformation in patients with chronic lymphocytic leukemia","volume":"132","author":"Ben-Dali","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0008","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter's syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.07.005_bib0009","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.07.005_bib0010","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0011","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.005_bib0012","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.005_bib0013","unstructured":"Wierda WG, Brown J, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2024, 2023. Accessed April 15, 2024. (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf)."},{"issue":"12","key":"10.1016\/j.clml.2024.07.005_bib0014","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0015","first-page":"360","article-title":"Sequential cis-platinum, fludarabine, and arabinosyl cytosine (PFA) or cyclophosphamide, fludarabine and arabinosyl cytosine (CFA) in patients with Richter's syndrome (RS): a pilot study","volume":"88","author":"Giles","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.07.005_bib0016","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/10428190290016872","article-title":"Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders","volume":"43","author":"Tsimberidou","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2024.07.005_bib0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2024.07.005_bib0018","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0019","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.005_bib0020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2024.07.005_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0022","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0023","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter's transformation in patients with chronic lymphocytic leukaemia: a nationwide epidemiological study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2024.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.07.005_bib0026","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.clml.2024.07.005_bib0028","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.07.005_bib0029","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.clml.2024.07.005_bib0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hon.3164_343","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome","volume":"41","author":"Davids","year":"2023","journal-title":"Hematol Oncol"},{"issue":"15","key":"10.1016\/j.clml.2024.07.005_bib0031","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.07.005_bib0032","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working P","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.07.005_bib0033","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.07.005_bib0034","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.07.005_bib0035","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","article-title":"Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration","volume":"106","author":"Stephens","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0036","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.07.005_bib0037","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.07.005_bib0038","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1097\/HS9.0000000000000870","article-title":"Alone and in combination with tislelizumab, for the treatment of richter transformation of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0039","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2023-181108","article-title":"Pirtobrutinib in Richter transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1\/2 BRUIN study","volume":"142","author":"Wierda","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2024.07.005_bib0040","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0041","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.07.005_bib0042","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2023.41.16_suppl.7502","article-title":"Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome","volume":"41","author":"Frustaci","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.07.005_bib0043","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter's syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0044","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.clml.2024.07.005_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter's transformation","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0046","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2023-173796","article-title":"Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory richter's transformation","volume":"142","author":"Cheah","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and efficacy of CD19-CAR T cells in richter's transformation after targeted therapy for chronic lymphocytic leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0048","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2023-180858","article-title":"Anti-CD19 chimeric antigen receptor t-cell therapy for Richter's transformation: an international multicenter retrospective study","volume":"142","author":"Kittai","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.07.005_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7010","article-title":"Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the center for international blood and marrow transplant research (CIBMTR)","volume":"42","author":"Winter","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.07.005_bib0050","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2024.07.005_bib0051","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0052","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1182\/blood-2022-159695","article-title":"Blinatumomab for patients with richter syndrome: final results of the phase 2 blinart trial from the filo group","volume":"140","author":"Guieze","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.07.005_bib0053","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.clml.2024.07.005_bib0054","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-138896","article-title":"A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed\/refractory richter's transformation and de novo diffuse large B-cell lymphoma","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0056","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/blood-2023-185569","article-title":"A prospective, phase-II study to evaluate the efficacy and safety of obinutuzumab, ibrutinib, and venetoclax (GIVeRS) in patients with richter's syndrome","volume":"142","author":"Tadmor","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.07.005_bib0057","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2024.07.005_bib0058","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.005_bib0059","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.07.005_bib0060","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2023-182559","article-title":"Safety, efficacy and T-Cell predictive biomarkers in a phase I trial of copanlisib+nivolumab in patients with Richter's transformation (RT) or transformed non-Hodgkin lymphoma (TNHL)","volume":"142","author":"Shouse","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.clml.2024.07.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971696.54506.b2","article-title":"Zilovertamab vedotin (Mk-2140) in relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL): updated results from the phase 1 waveline-001 study","volume":"7","author":"Spurgeon","year":"2023","journal-title":"HemaSphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:13Z","timestamp":1739364433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024002623"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}